MX2016004329A - Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. - Google Patents

Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.

Info

Publication number
MX2016004329A
MX2016004329A MX2016004329A MX2016004329A MX2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A
Authority
MX
Mexico
Prior art keywords
benralizumab
methods
chronic obstructive
obstructive pulmonary
treating chronic
Prior art date
Application number
MX2016004329A
Other languages
English (en)
Spanish (es)
Inventor
Wang Bing
Roskos Lorin
Ward Christine
Van Der Merwe Rene
Martin Ubaldo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2016004329A publication Critical patent/MX2016004329A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016004329A 2013-10-15 2014-10-14 Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. MX2016004329A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US201461970126P 2014-03-25 2014-03-25
PCT/US2014/060432 WO2015057668A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Publications (1)

Publication Number Publication Date
MX2016004329A true MX2016004329A (es) 2016-11-10

Family

ID=52809872

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016004329A MX2016004329A (es) 2013-10-15 2014-10-14 Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
MX2019013468A MX2019013468A (es) 2013-10-15 2016-04-04 Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019013468A MX2019013468A (es) 2013-10-15 2016-04-04 Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.

Country Status (12)

Country Link
US (4) US20150104447A1 (cg-RX-API-DMAC7.html)
EP (2) EP3057609A4 (cg-RX-API-DMAC7.html)
JP (3) JP2016534996A (cg-RX-API-DMAC7.html)
KR (1) KR20160061352A (cg-RX-API-DMAC7.html)
CN (2) CN105636607A (cg-RX-API-DMAC7.html)
AU (2) AU2014334563A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016008082A2 (cg-RX-API-DMAC7.html)
CA (1) CA2925402A1 (cg-RX-API-DMAC7.html)
MX (2) MX2016004329A (cg-RX-API-DMAC7.html)
RU (1) RU2706729C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201807318RA (cg-RX-API-DMAC7.html)
WO (1) WO2015057668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164157B (zh) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
CN110981957B (zh) 2014-01-15 2024-12-24 豪夫迈·罗氏有限公司 具有改善的蛋白A结合作用的Fc区变体
AU2016272399B2 (en) 2015-06-01 2021-09-09 Kyowa Kirin Co., Ltd. Therapeutic agent and therapeutic method for pulmonary hypertension
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
JP7696900B2 (ja) * 2019-12-06 2025-06-23 サノフィ・バイオテクノロジー Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法
EP3957308A1 (en) * 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
PT1176195E (pt) * 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
AU2001232304A1 (en) * 2000-02-15 2001-08-27 Kyowa Hakko Kogyo Co. Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
US20100291073A1 (en) * 2007-05-14 2010-11-18 Medimmune, Llc Methods of reducing eosinophil levels
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
RU2013122123A (ru) * 2010-10-15 2014-11-20 Медиммьюн Лимитед Терапевтические средства для улучшения легочной функции
EP2652498B1 (en) * 2010-12-16 2018-04-18 F.Hoffmann-La Roche Ag Diagnosis and treatments relating to th2 inhibition
US8961965B2 (en) * 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
CN104039352A (zh) * 2011-11-01 2014-09-10 米迪缪尼有限公司 用于降低哮喘急性恶化的频率和严重性的方法
SG11201600484TA (en) * 2013-08-12 2016-02-26 Medimmune Llc Methods for improving asthma symptoms using benralizumab
HUE042607T2 (hu) * 2013-08-12 2019-07-29 Astrazeneca Ab Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával
CN111588849A (zh) * 2013-08-12 2020-08-28 阿斯特拉捷利康股份公司 使用贝那利珠单抗增加哮喘患者用力呼气量的方法

Also Published As

Publication number Publication date
MX2019013468A (es) 2020-02-12
SG11201601807XA (en) 2016-04-28
BR112016008082A2 (pt) 2017-10-17
WO2015057668A1 (en) 2015-04-23
CN113230399A (zh) 2021-08-10
RU2706729C2 (ru) 2019-11-20
CN105636607A (zh) 2016-06-01
CA2925402A1 (en) 2015-04-23
KR20160061352A (ko) 2016-05-31
RU2016118425A3 (cg-RX-API-DMAC7.html) 2018-07-19
JP2016534996A (ja) 2016-11-10
US20200123262A1 (en) 2020-04-23
SG10201807318RA (en) 2018-09-27
JP2021107421A (ja) 2021-07-29
US20180291108A1 (en) 2018-10-11
JP2019203009A (ja) 2019-11-28
AU2014334563A1 (en) 2016-04-07
AU2020202333A1 (en) 2020-04-23
RU2016118425A (ru) 2017-11-21
EP3485902A1 (en) 2019-05-22
US20170107291A1 (en) 2017-04-20
JP6870037B2 (ja) 2021-05-12
EP3057609A4 (en) 2017-03-22
EP3057609A1 (en) 2016-08-24
US20150104447A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
PH12015502075A1 (en) Treatment of cataplexy
MX2023000079A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento de sinusitis cronica con polipos nasales.
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
PL3791896T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
PH12015501108A1 (en) Treatment of pulmonary disease
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
MX368068B (es) Antagonista de il-4r para usarse para tratar la poliposis nasal.
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
NZ710726A (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
EA201990684A1 (ru) Способы применения оксигенированных холестеролсульфатов (ocs)
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX2016001383A (es) Metodos para reducir la tasa de exacerbacion de asma mediante el uso de benralizumab.
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
MX2014001764A (es) Inhibidor de alfa1-proteinasa para demorar el comienzo o progresion de exacerbaciones pulmonares.
MX2016001384A (es) Metodos para incrementar el volumen espiratorio forzado en pacientes asmaticos que usan benralizumab.
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
EA201491581A1 (ru) Везикулярные композиции
EA201792282A1 (ru) Способы лечения заболеваний
EA201690446A1 (ru) Лечение множественной миеломы
EA201690445A1 (ru) Лечение рака